文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

预测急性肾损伤成功脱离肾脏替代治疗的新型生物标志物:一项系统评价

Novel biomarkers for predicting successful liberation of renal replacement therapy for acute kidney injury: a systematic review.
PubMed 文献 · Crit Care · 2025-05-26
一句话结论系统评价显示尿NGAL对重症AKI患者短期成功脱离RRT具有中等预测能力(AUC 0.766),其他生物标志物尚需验证。

该系统评价纳入16项研究共3020例重症AKI患者,评估23种新型生物标志物预测成功脱离RRT的能力。尿NGAL(uNGAL)在4项研究中显示中等预测性能(AUC 0.766,I2=39.8%);排除一项关注长期结局的研究后,预测能力更佳且异质性低(AUC 0.801,I2=0%)。血浆脑啡肽原A(PENK)和血清NGAL也显示潜力,但因研究数量少和异质性大而无法定量合成。切点值差异大,限制了临床转化;新型生物标志物联合临床指标的模型显示出前景,但研究有限且结论不一致,需进一步探索。

要点

  • 在重症AKI患者中,uNGAL对短期成功脱离RRT具有中等预测能力(4项研究,AUC 0.766,I2=39.8%)。
  • 排除一项关注长期结局的研究后,uNGAL预测能力更佳且异质性低(AUC 0.801,I2=0%)。
  • 血浆PENK和血清NGAL也显示预测潜力,但因研究数量少和异质性大而无法定量合成。
  • 各研究切点值差异广泛,限制了生物标志物的临床转化。
  • 新型生物标志物联合临床指标(如尿量)的多变量模型显示出前景,但研究有限且结论不一致,需进一步探索。

适用人群与场景

  • 重症监护病房中因急性肾损伤接受肾脏替代治疗的危重症患者。

研究设计与关键结果

  • 系统评价纳入16项研究、共3020例患者,涉及23种生物标志物。
  • uNGAL在4项研究中显示中等预测性能(AUC 0.766,I2=39.8%)。
  • 排除一项关注长期结局的研究后,uNGAL预测能力更佳且异质性低(AUC 0.801,I2=0%)。
  • 血浆PENK和血清NGAL也显示潜力,但因研究数量少和异质性大而无法定量合成。
  • 各研究切点值差异广泛,限制了临床转化。
  • 新型生物标志物联合临床指标的多变量模型显示出前景,但研究有限且结论不一致,需进一步探索。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,遵循PRISMA指南,检索PubMed、Embase和Scopus至2025年5月2日,使用Newcastle-Ottawa量表评估方法学质量。
  • 局限:纳入研究数量有限且结论不一致;切点值差异广泛;部分生物标志物因研究数量少和异质性大而无法定量合成。
  • 局限:需要进一步大规模、前瞻性、多中心研究验证这些发现。

对床旁实践的改变

  • uNGAL可能有助于预测重症AKI患者短期成功脱离RRT(AUC 0.766),但切点值差异大,尚未形成标准化阈值。
  • 作者认为,标准化成功脱离的定义并将动态生物标志物变化与临床指标(如尿量)整合,可能提高预测准确性。
  • 其他生物标志物(如PENK)尚需进一步验证,暂不能用于床旁决策。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Renal replacement therapy (RRT) is commonly used in critically ill patients with acute kidney injury (AKI). However, optimal timing of RRT liberation remains controversy. This meta-analysis evaluates novel biomarkers to predict successful RRT liberation in critically ill AKI patients.

METHODS: The systematic review reported following PRISMA guidelines, PubMed, Embase, and Scopus were searched up to May 2, 2025, and were screened using predefined criteria. Methodological quality was assessed using the Newcastle-Ottawa scale. Pooled ROC-AUCs with 95% CIs were calculated; heterogeneity was evaluated using I2 statistics.

RESULTS: Sixteen studies (3020 patients) involving 23 biomarkers were included. Urinary neutrophil gelatinase-associated lipocalin (uNGAL) demonstrated fair predictive performance with 4 studies (AUC 0.766, I2 = 39.8%). When excluding a study focused on long-term outcomes, the result showed a better predictive ability with low heterogeneity (AUC 0.801, I2 = 0%). Plasma proenkephalin A (PENK) and serum NGAL also showed potential, but quantitative synthesis was limited by study number and heterogeneity. The cut-off value also varied widely, complicating clinical translation. In addition, multivariable models combining novel biomarkers with clinical indicators have also demonstrated promising predictive potential. However, due to the limited number of studies and inconsistent conclusions, further exploration is needed.

CONCLUSION: uNGAL moderately predicts short-term RRT liberation, while other biomarkers (e.g., PENK) require further validation. Standardizing definitions of successful liberation and integrating dynamic biomarker changed with clinical indicators (e.g., urine output) may enhance predictive accuracy. Further large-scale, prospective, and multicenter studies are needed to validate these findings.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Xu Q, Zhou Z, Jin L, et al. Novel biomarkers for predicting successful liberation of renal replacement therapy for acute kidney injury: a systematic review. Crit Care. 2025. PMID: 40420198. doi:10.1186/s13054-025-05451-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。